Pharmacists in Fulton, KY Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Benjamin H Whitesell Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1405 Middle Rd, Fulton, KY 42041 Phone: 270-472-9802 |
Michael Patrick Prather, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1405 Middle Rd, Fulton, KY 42041 Phone: 270-472-9802 Fax: 270-472-9811 |
 Elizabeth Jane Campbell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1405 Middle Rd, Fulton, KY 42041 Phone: 270-472-9802 |
Dr. David Stewart Prater Jr., PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 208 Lake St, Fulton, KY 42041 Phone: 270-472-2984 Fax: 270-472-9377 |
Dr. Amelia Alexander Prater, PHARM D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 208 Lake St, C/ O Evans Total Care, Llc, Fulton, KY 42041 Phone: 270-472-2984 |
Mr. Reginald David Woolf, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 212 Lake St, Fulton, KY 42041 Phone: 270-472-2421 |
News Archive
More objective testing may reduce cost and risk of managing GERD, study suggests
There are significant cost and risk factors associated with two procedures commonly used to diagnose or treat gastrointestinal problems, according to research presented at Digestive Disease Week.
Investment report on Idenix Pharmaceuticals
StockPreacher.com announces an investment report featuring Idenix Pharmaceuticals Inc.. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
New set of research priorities identified to support tobacco control
A new set of research priorities to support tobacco control will help ensure future research provides the greatest benefit to public health and value for money, according to an international group led by Oxford University researchers.
BIO President comments on introduction of Patent Reform Act of 2011
Biotechnology Industry Organization President and CEO Jim Greenwood released the following comment on the introduction of the Patent Reform Act of 2011 (S. 23) by Senate Judiciary Committee Chairman Patrick Leahy (D-VT) earlier this week
Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial
Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
› Verified 9 days ago